{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zaorsky NG"],"funding":["NCI NIH HHS"],"pagination":["386-393"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7548033"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["126(3)"],"pubmed_abstract":["<h4>Background and purpose</h4>To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin.<h4>Materials and methods</h4>Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as \"good,\" \"fair,\" or \"poor.\" The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED<sub>3</sub>) and cosmetic outcomes.<h4>Results</h4>A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 ye"],"journal":["Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"],"pubmed_title":["Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis."],"pmcid":["PMC7548033"],"funding_grant_id":["P30 CA006927"],"pubmed_authors":["Zhang E","Zaorsky NG","Lee CT","Galloway TJ"],"additional_accession":[]},"is_claimable":false,"name":"Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.","description":"<h4>Background and purpose</h4>To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin.<h4>Materials and methods</h4>Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as \"good,\" \"fair,\" or \"poor.\" The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED<sub>3</sub>) and cosmetic outcomes.<h4>Results</h4>A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 ye","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2025-04-26T11:53:42.671Z","creation":"2025-04-06T13:51:20.548Z"},"accession":"S-EPMC7548033","cross_references":{"pubmed":["29370985"],"doi":["10.1016/j.radonc.2017.12.029"]}}